Combined Modality Therapy With Growth Factor Support in Locally Advanced Non-small Cell Lung Cancer (NSCLC)
Status:
Completed
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
To determine the safety and efficacy of administering filgrastim with concurrent
chemoradiotherapy and the potential benefit of administering pegfilgrastim with consolidation
chemotherapy in patients with unresectable locally advanced NSCLC patients.